Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review.

Fabrice JollantRomain ColleThi Mai Loan NguyenEmmanuelle CorrubleAlain M GardierMartin WalterMocrane AbbarGerd Wagner

Published in: Therapeutic advances in psychopharmacology (2023)

Overall, there is compelling evidence for a favorable short-term benefit-risk balance with intravenous racemic ketamine but not intranasal esketamine. The place of ketamine will have to be defined within a multimodal care strategy for suicidal patients. Caution remains necessary for clinical use, and pharmacovigilance will be essential.

Keyphrases

pain management
depressive symptoms
end stage renal disease
ejection fraction
newly diagnosed
palliative care
prognostic factors
high dose
quality improvement
emergency department
chronic pain
low dose